Our specialist multi-disciplinary LIFE SCIENCES team advises businesses at all stages of the medicines supply chain

Life Sciences

Our multi-disciplinary life sciences team advises a wide range of clients in the life sciences sector including some of the world’s largest pharmaceutical companies, biotech companies, healthcare providers and medical devices manufacturers. 

We advise life sciences companies at all stages of the medicines supply chain on the full range of legal issues affecting them including competition, regulatory and compliance, intellectual property including patents and trade marks, product life cycle, clinical trial agreements, collaboration, licensing and other commercial transactions.

We also have extensive experience of advising on acquisitions in the life sciences area and in advising banks and financial institutions with an interest in this space.



  • Intellectual Property

    Intellectual property rights are of vital importance to companies in the life sciences sector and are often the most valuable assets of the business. We can help companies in the life sciences and healthcare space to effectively and efficiently protect and exploit their intellectual property rights.

    We have extensive experience of handling litigation at all levels of the UK courts, as well as managing multi-jurisdiction disputes and working with leading IP practitioners in the overseas territories in which our clients are active. However, an equally important aspect of our work is advising on the effective protection, use and licensing of IP rights to maximise our clients’ commercial advantage and prevent disputes arising. Our team advises on the full range of contentious and non-contentious intellectual property including patent litigation and licensing, and trade secrets litigation.

  • Commercial Agreements

    Our Commercial team has extensive experience and in-house expertise of the legal issues that affect life sciences and healthcare companies on a daily basis.

    Our experience extends to generics, animal health, eye care, innovators, manufacturers, vaccines, medical devices as well as biotech and delivery systems. In particular, we work closely with in-house life science and pharmaceutical teams and regularly assist with the drafting, negotiation and termination of commercial agreements. These include NDAs, clinical trials, joint working agreements and collaboration arrangements, sales or purchase terms, rebates, sales of marketing authorisations. We also advise on manufacturing and supply contracts, warehousing and logistics, standard template agreements, appointment of field sales teams, outsourcing and procurement and licensing and marketing contracts.

  • Competition and EU law

    Ensuring compliance with competition law should be a key priority of any life sciences and healthcare business.  Because of the importance of the sector to the global economy, and the dynamic nature of life sciences markets, the sector is, and will continue to be, a high priority for enforcement.  Competition law can also provide an opportunity for businesses to ensure that competitors play fair, and can result in substantial damages being awarded for infringements.

    Our competition team is hugely experienced in the life sciences sector.  We have many years’ experience of working with regulators and companies in this area.  Experience includes advisory work, implementing compliance training, acting in relation to government investigations and dawn raids and carrying out litigation including judicial review of government policy.

  • Regulatory

    Pharmaceutical and biotechnology businesses are subject to a huge range of regulations.  In addition to general regulations (e.g. anti-bribery and corruption, competition law and data privacy), life sciences businesses are required to comply with a range of sector specific regulations and voluntary schemes.

    We have experience of advising on both general and sector specific regulations impacting life sciences businesses.  We have provided compliance training and have assisted businesses on issues as they arise.  These include government investigations, including dawn raids, issues arising in the context of commercial and corporate transactions and day to day issues facing businesses.

  • Dispute Resolution

    We have considerable experience of handling disputes arising for clients in the life sciences sector over many years. We often work closely with the client’s in-house team and have developed a detailed understanding of the sector and what is important for their businesses.

    Our work involves advice on issues as they emerge, mediation, litigation and arbitration.  Where urgent situations arise we have considerable experience of seeking injunctive relief to prevent damage or loss.

    In addition to disputes arising under licensing, supply and development agreements, we also deal with other issues such as product recall and claims arising. We also act for life sciences clients in relation to construction and engineering disputes.  

    Examples of our experience include:

    - Successfully representing a multinational pharmaceutical company relating to a multi-million pound cross-border fraud to obtain freezing and seizure orders

    - Acting for pharmaceutical clients in relation to dawn raids by the SFO on their UK offices

    - Acted for an international life sciences company in an ICC arbitration against a foreign life sciences company 

  • Corporate and Banking

    We have experience of advising both buyers and sellers of companies and businesses in the pharmaceutical, life sciences and healthcare sectors. This includes management teams on leveraged transactions.

    We have advised on equity fundraisings including private equity and development capital transactions and debt transactions including traditional senior bank debt but also warrants and other forms of finance.

  • Data Protection

    Data protection issues are now high profile and often come under the spotlight.  We act for organisations looking to resist Freedom of Information requests or dealing with Data Protection or data licensing issues. The arrival of the General Data Protection Regulations means that we are helping many organisations to prepare for its impact. Our team is well versed in data protection issues and has in-house experience for a worldwide major pharmaceutical company on data protection issues.

    Our advice covers data licensing, dealing with sensitive personal data, data breaches, appointment of data processors in outsourced IT and services, transfers of personal data outside the EEA, making and resisting data subject access requests and freedom of information requests. We draft privacy and cookies notices, advise on notifications to the Information Commissioner’s office and assist in the preparation of policies and standard operating procedures including for surveillance and interception of emails and privacy impact assessments.

    We work closely with our international colleagues on trans-border transactions and provide advice on implementation of the General Data Protection Regulations.

Our experience

  • Advising the UK stakeholders responsible for UK’s overall implementation of the Falsified Medicines Directive
  • Advising an international pharmaceutical company on complex patent, regulatory and data protection issues
  • Assisting a global pharmaceutical company on successful Judicial Review of Home Office policy

Uber loses appeal on worker status in the Employment Appeal Tribunal

The Employment Appeal Tribunal has recently given its decision in the case of Uber BV and others v Aslam and others holding that Uber drivers are workers and therefore entitled, amongst other things, to paid holidays and the minimum wage.   Facts ...

Read more

Less revenue and control for landlords from the new Electronic Communications Code

Louise Kellaway and Jonathan Cope from our Real Estate Team review how forthcoming changes to The Electronic Communication Code will impact landlords in a recent article in Landlord Today. Please see the full article here .  ...

Read more

European Medicines Agency gets ready for relocation

It is not long now until the EMA announces its new host city, with applications from Amsterdam to Zagreb. See our note EMA: Preparing for Brexit for the full list of cities and the selection criteria. After the announcement on 20 November 2017, the EMA...

Read more

Fairness of Dismissal and Knowledge of a Protected Disclosure

Fairness of Dismissal and Knowledge of a Protected Disclosure: Fairness of a dismissal should be based on what the decision-maker knew and not what they should have known. In Royal Mail Ltd v Jhuti [2017] the Court of Appeal considered whether an...

Read more

New draft guidelines on GDPR mandatory breach notifications

One of the key changes under the GDPR will be the change to reporting personal data breaches. Under the current legislation, most organisations are not generally legally required to report personal data breaches, albeit it is good practice to...

Read more

Court confirms the late payment legislation does not provide automatic entitlement to costs in adjudication

There has been some debate as to whether or not legal costs incurred in pursuing debt claims in adjudication might be recoverable under the Late Payment of Commercial Debts Interest Act 1998. In an article published last year , I counseled against any...

Read more

The only way is up...what the Base Rate change means for corporate borrowers

Last week the Bank of England increased its Base Rate from 0.25% to 0.50%. This is the first such rate change since 2007, reversing the 0.25% cut that was made last summer following the Brexit referendum result. For many the rate change comes as no...

Read more

Risk assessment for breastfeeding mothers

In the case of Ramos v Servicio Galego de Saude , the European Court of Justice has recently held that a failure by an employer to carry out an appropriate workplace risk assessment, based on the individual circumstances of a breastfeeding worker, was...

Read more

New corporate offence: failing to prevent the facilitation of tax evasion

A new corporate offence of failing to prevent the facilitation of tax evasion came into force on 30 September 2017 under the Criminal Finances Act 2017 (the “CFA 2017”). Employers will commit an offence under the CFA 2017 if they fail to prevent...

Read more

Mondolez drops litigation against Poundland over trademark infringement

Mondolez has recently agreed to drop its trademark infringement litigation against Poundland.  The confectionery company had filed a legal challenge over the budget chain's version of Toblerone. S&B's Elaine O'Hare comments in...

Read more

Employment Tribunal refund scheme starts

The government has launched the first phase of the employment tribunal fee refund scheme following the Supreme Court decision in July that Tribunal fees were unlawful. In this initial phase, approximately 1,000 eligible parties will be contacted to apply for...

Read more

Employment Tribunal fees refund scheme starts

The government has launched the first phase of the employment tribunal fee refund scheme following the Supreme Court decision in July that Tribunal fees were unlawful. In this initial phase, approximately 1,000 eligible parties will be contacted to apply for...

Read more

Protecting live music IP with blockchain

Joanna Morris from our IP Team has published an article in IQ Magazine on  how blockchain or a 'distributed ledger system' can help those in the live music industry safeguard their creative works. Please see the full article here ....

Read more

When are insolvency proceedings appropriate? Top tips for avoiding abuse of process.

The recent judgment in the case of Bernhards Sports Surfaces Ltd v Astrosoccer4u Ltd [2017] EWHC 2425 (TCC) has provided a sage reminder that insolvency proceedings should only be threatened and/or utilised in circumstances where a company is genuinely...

Read more

Merck v Merck - Trade mark battle

Many EU trade mark owners own parallel national trade marks in key jurisdictions in order to strengthen their trade mark portfolios.  A recent Court of Justice (CJEU) decision (19 October 2017) considered the situation where infringement proceedings are...

Read more

Former employee fined for unlawfully obtaining personal data

An ex-employee was prosecuted in the Magistrates Court recently for taking personal information without his employer’s consent. He was also condemned by the Information Commissioner’s Office (‘ICO’). Background Mr Morar took the...

Read more

Twenty-first century wills: Australian Court rules unsent text message is a valid will

A recent decision of the Brisbane Supreme Court reported by various news outlets has highlighted the different approach taken by other countries to the formality requirements of wills.  Justice Susan Brown ruled that an unsent text message found in the...

Read more

Brexit update - economic and social impacts

The Migration Advisory Committee (‘MAC’), the independent non-departmental public body that advises the Government on migration issues, will be reporting on the economic and social impacts of Brexit in September 2018.  Employers will be...

Read more

Sports Brands: challenging counterfeiting and unauthorised goods

There are many challenges presented by counterfeit and unauthorised goods in the sports industry. Tom Collins, associate in the IP team at Stevens & Bolton, examines some of the high-profile cases in the industry and recent legal...

Read more

Moving the loan goal posts: was a personal guarantee shown the red card?

Most lenders require corporate borrowers to provide security for a loan to protect their position should that borrower default under their loan transaction.  Lenders want as much “security” as they can get on any given transaction which...

Read more

ICO confirms data controller fees for 2018

Although the registration process will be dispensed with under GDPR, the ICO has confirmed that data controllers will still be subject to fees next year, once the GDPR starts to apply. Under the existing law, controllers must (unless exempt) register with...

Read more

Grey market sales - minimising the risk of liability

A recent ruling by the Supreme Court has confirmed that criminal sanctions apply to grey market sales. Tom Collins and Camille Arnold from Stevens & Bolton's IP team look at how retailers can minimise the risks of liability in an...

Read more

European Medicines Agency relocation: preparing for Brexit

The vote on the European Medicines Agency (EMA) post-Brexit relocation is fast approaching and as a result there has been quite a lot of Brexit related activity recently, with some issues raising real concerns.   Relocation – where to next? ...

Read more

Keeping it in suspense - the use and limits of Suspense Accounts

Matthew Padian, a Senior Associate in the Banking & Finance practice at Stevens & Bolton, has recently contributed an article to the Butterworths Journal of International Banking and Financial Law on the topic of suspense accounts. The right to open...

Read more

How should retailers cope with the challenging market conditions in the lead up to Christmas?

Last week DFS revealed a sharp fall in pre-tax profits of 22.3% in the year to 29 July, despite the company having announced its acquisition of fellow sofa retailer Sofology and also having experienced an increase in revenue over the year. The chairman...

Read more

Rebranding of High Court specialist courts - live from 2 October 2017

As of 2 October 2017, the High Court business specialist courts have rebranded. The Commercial Court, The Commercial Circuit Court (formerly the Mercantile Court), the Admiralty Court,  the Technology and Construction Court of the Queen’s Bench...

Read more

ASA holds business responsible for non-compliant advertising by affiliates

The Advertising Standards Agency (ASA) has held a number of businesses liable for non-compliant advertisements published by their affiliate marketers. The cases serve as a clear reminder to businesses of the risks of incurring liability and negative...

Read more

Another article on Artificial Intelligence

It is pretty much mandatory these days for law firms to write about the impact of artificial intelligence (AI).  We thought we would jump on the bandwagon, before it becomes entirely populated by robots.   In the life sciences sector, there are a...

Read more

Update: Further Developments on the Health Services Medical Supplies (Costs) Act 2017

We previously wrote about the new Health Services Medical Supplies (Costs) Act ( see here ). This important Act paved the way for the Government to gain greater control over excessive pricing of health services medicines and greater access to information...

Read more

Monarch enters administration - what protections are available?

On Monday 2 October, Monarch (the UK’s fifth largest airline) entered administration after discussions with the Civil Aviation Authority (“CAA”) to renew its licence to sell package holidays failed. The airline reported a loss of...

Read more
  • Page 1 of 10

Search our site